Rankings
▼
Calendar
CLDX
Celldex Therapeutics, Inc.
$2B
Q2 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1M
Gross Profit
-$48M
-3468.7% margin
Operating Income
-$32M
-2330.2% margin
Net Income
-$32M
-2300.4% margin
EPS (Diluted)
$-4.85
QoQ Revenue Growth
+6.6%
Cash Flow
Operating Cash Flow
-$34M
Free Cash Flow
-$35M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$271M
Total Liabilities
$36M
Stockholders' Equity
$235M
Cash & Equivalents
$32M
Revenue Segments
Pd1 Immune Checkpoint Inhibitor
$600,000
100%
← FY 2016
All Quarters
Q3 2016 →
CLDX Q2 2016 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
